Illumina, Inc.
Illumina, Inc. Terminates Credit Agreement and Issues New Notes
Summary
On September 4, 2024, Illumina, Inc. entered into an Underwriting Agreement for the issuance of $500 million in 4.650% notes due 2026, which it used to repay its outstanding indebtedness under a terminated 364-day delayed draw credit agreement. The notes were issued under an Indenture dated March 12, 2021, and will accrue interest at a rate of 4.650% per annum, payable semi-annually, with maturity on September 9, 2026.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement